上海仁度生物科技股份有限公司 关于公司首次公开发行部分限售股上市流通的公告

Core Viewpoint - The company is set to release 8,431,604 restricted shares for trading on September 30, 2025, following a 42-month lock-up period since its initial public offering (IPO) [4][5][21]. Group 1: Stock Listing Details - The type of stock listing is for the first issuance of restricted shares, with a total of 8,431,604 shares to be listed [2][3]. - The total number of shares after the IPO was 40,000,000, with 31,818,377 shares (79.55%) being restricted and 8,181,623 shares (20.45%) being unrestricted [5]. - The restricted shares being released are held by two shareholders and represent 21.04% of the total share capital [5]. Group 2: Shareholder Commitments - The controlling shareholder, Ju Jinliang, has committed to not transferring or managing the shares held prior to the IPO for 36 months and has additional conditions for extending the lock-up period if the stock price falls below the IPO price [7][8]. - There are specific commitments regarding the sale of shares after the lock-up period, including a requirement that any sales must not be below the IPO price and must be disclosed in advance [14][17]. - The company has confirmed that there are no instances of fund occupation by the controlling shareholder or related parties [21]. Group 3: Regulatory Compliance - The company has received approval from the China Securities Regulatory Commission for the public issuance of shares and has complied with the relevant regulations for the listing of restricted shares [5][21]. - The underwriter has verified that the company has adhered to the commitments regarding share lock-up and that the information disclosed is accurate and complete [21].